dc.creatorToscanini, María Agustina
dc.creatorLimeres, María José
dc.creatorVidela Garrido, Agustin
dc.creatorCagel, Carlos Maximiliano
dc.creatorBernabeu, Ezequiel Adrian
dc.creatorMoretton, Marcela Analía
dc.creatorChiappetta, Diego Andrés
dc.creatorCuestas, María Luján
dc.date.accessioned2022-09-28T10:59:52Z
dc.date.accessioned2022-10-15T07:44:25Z
dc.date.available2022-09-28T10:59:52Z
dc.date.available2022-10-15T07:44:25Z
dc.date.created2022-09-28T10:59:52Z
dc.date.issued2021-12
dc.identifierToscanini, María Agustina; Limeres, María José; Videla Garrido, Agustin; Cagel, Carlos Maximiliano; Bernabeu, Ezequiel Adrian; et al.; Polymeric micelles and nanomedicines: Shaping the future of next generation therapeutic strategies for infectious diseases; Editions Sante; Journal of Drug Delivery Science and Technology; 66; 12-2021; 1-24
dc.identifier1773-2247
dc.identifierhttp://hdl.handle.net/11336/170719
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4361833
dc.description.abstractDespite all the advances in understanding the pathogenesis of infectious diseases and the development of novel treatments to combat them, these pathogenic disorders are among the most common reasons for hospitalizations and death worldwide. Polymeric micelles (PMs) are nano-sized drug delivery systems that in the last few years have raised special attention for optimizing the therapy of many infectious diseases, including those considered as neglected by the World Health Organization. These nanoscopic core/shell structures formed by self-assemblies of amphiphilic block copolymers represent an effective delivery system for poorly water-soluble drugs. In the last few years, many micellar formulations were studied for delivery of drugs, genes and nutraceuticals, and some of them are under clinical trials. This review will focus on the applications of polymeric single and mixed micelles for the treatment of infectious diseases and will discuss how these advancements have contributed to improve their pharmacotherapy, with a special emphasis on neglected tropical diseases. A summary of the nanomaterials used for the preparation of PMs is detailed. The current state of the art of several micellar formulations as nanocarriers of FDA-approved drugs for the therapy of many infectious diseases, including those under pre-clinical or clinical trials is provided. Finally, perspectives in the design of a more efficient pharmacotherapy to overcome the multi-drug resistance phenotype of pathogens or host cells are addressed.
dc.languageeng
dc.publisherEditions Sante
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S1773224721006079
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.jddst.2021.102927
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectBIOMATERIALS
dc.subjectINFECTIOUS DISEASES
dc.subjectMIXED MICELLES
dc.subjectNEGLECTED TROPICAL DISEASES
dc.subjectPOLYMERIC MICELLES
dc.titlePolymeric micelles and nanomedicines: Shaping the future of next generation therapeutic strategies for infectious diseases
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución